{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:09Z","timestamp":1786980489206,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Faculty of Medicine, Thammasat University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10067-020-05262-6","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T03:02:46Z","timestamp":1593486166000},"page":"255-262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout"],"prefix":"10.1007","volume":"40","author":[{"given":"Ratchaya","family":"Lertnawapan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9301-8941","authenticated-orcid":false,"given":"Kanon","family":"Jatuworapruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"issue":"1","key":"5262_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12882-019-1274-5","volume":"20","author":"JA Singh","year":"2019","unstructured":"Singh JA, Cleveland JD (2019) Gout is associated with a higher risk of chronic renal disease in older adults: a retrospective cohort study of U.S. Medicare population. BMC Nephrol 20(1):93. https:\/\/doi.org\/10.1186\/s12882-019-1274-5","journal-title":"BMC Nephrol"},{"key":"5262_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3899\/jrheum.190346","volume":"47","author":"MM Elfishawi","year":"2019","unstructured":"Elfishawi MM, Zleik N, Kvrgic Z, Michet CJ Jr, Crowson CS, Matteson EL, Bongartz T (2019) Changes in the presentation of incident gout and the risk of subsequent flares: a population-based study over 20 years. J Rheumatol 47:613\u2013618. https:\/\/doi.org\/10.3899\/jrheum.190346","journal-title":"J Rheumatol"},{"issue":"1","key":"5262_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12891-019-2519-y","volume":"20","author":"P Towiwat","year":"2019","unstructured":"Towiwat P, Chhana A, Dalbeth N (2019) The anatomical pathology of gout: a systematic literature review. BMC Musculoskelet Disord 20(1):140. https:\/\/doi.org\/10.1186\/s12891-019-2519-y","journal-title":"BMC Musculoskelet Disord"},{"issue":"8","key":"5262_CR4","first-page":"393","volume":"10","author":"J Foody","year":"2017","unstructured":"Foody J, Turpin RS, Tidwell BA, Lawrence D, Schulman KL (2017) Major cardiovascular events in patients with gout and associated cardiovascular disease or heart failure and chronic kidney disease initiating a xanthine oxidase inhibitor. Am Health Drug Benefits 10(8):393\u2013401","journal-title":"Am Health Drug Benefits"},{"issue":"10","key":"5262_CR5","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP et al (2012) American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64(10):1431\u20131446. https:\/\/doi.org\/10.1002\/acr.21772","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"5262_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Liot\u00e9 F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209707","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"5262_CR7","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/rheumatology\/kex250","volume":"56","author":"M Hui","year":"2017","unstructured":"Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, Jenkins W, Jordan KM, Mallen CD, McDonald TM, Nuki G, Pywell A, Zhang W, Roddy E, for the British Society for Rheumatology Standards, Audit and Guidelines Working Group (2017) The British Society for Rheumatology guideline for the management of gout. Rheumatology (Oxford) 56(7):1246. https:\/\/doi.org\/10.1093\/rheumatology\/kex250","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"5262_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","volume":"54","author":"M Lerch","year":"2018","unstructured":"Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T (2018) Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol 54(1):147\u2013176. https:\/\/doi.org\/10.1007\/s12016-017-8654-z","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"5262_CR9","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12(2):R63. https:\/\/doi.org\/10.1186\/ar2978","journal-title":"Arthritis Res Ther"},{"key":"5262_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13075-015-0624-3","volume":"17","author":"JA Singh","year":"2015","unstructured":"Singh JA, Akhras KS, Shiozawa A (2015) Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res Ther 17:120. https:\/\/doi.org\/10.1186\/s13075-015-0624-3","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"5262_CR11","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","volume":"72","author":"K Kimura","year":"2018","unstructured":"Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y, Kimura K, Hosoya T, Ito S, Inaba M, Tomino Y, Uchida S, Makino H, Matsuo S, Yamanaka H, Yamamoto T, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Akizawa T, Teramoto T, Kasanuki H, Yoshimura K, Kimura K, Hosoya T, Shibagaki Y, Ohno I, Sato H, Uchida S, Horikoshi S, Maruyama S, Inaba M, Moriwaki Y, Uchida H, Kaneshiro N, Imai N, Moriya H, Komatsu Y, Kaname S, Hanaoka K, Ogura M, Ikeda M, Kasai K, Sugiura A, Takahashi K, Kojima K, Nitta K, Tamai H, Nagaya H, Okuno S, Kakiya R, Takeoka H, Hirata K, Asano K, Fukaya Y, Iwaida Y, Tsuneda Y, Nishimura S, Hiramatsu T, Isaka Y, Ito T, Yuzawa Y, Yamagata K, Sofue T, Jinguji Y, Hirano K, Matsuyama K, Mizumoto T, Shibuya Y, Sugawara M, Kadomura M, Teshima Y, Ohtani H, Kamata H, Okawara S, Fukushima M, Takemura K, Kinugasa E, Kogure M, Ehara Y (2018) Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis 72(6):798\u2013810. https:\/\/doi.org\/10.1053\/j.ajkd.2018.06.028","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"5262_CR12","doi-asserted-by":"publisher","first-page":"e1003095","DOI":"10.1371\/journal.pmed.1003095","volume":"17","author":"A Tanaka","year":"2020","unstructured":"Tanaka A, Taguchi I, Teragawa H, Ishizaka N, Kanzaki Y, Tomiyama H, Sata M, Sezai A, Eguchi K, Kato T, Toyoda S, Ishibashi R, Kario K, Ishizu T, Ueda S, Maemura K, Higashi Y, Yamada H, Ohishi M, Yokote K, Murohara T, Oyama JI, Node K, on behalf of the PRIZE study investigators (2020) Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: a randomized, controlled trial. PLoS Med 17(4):e1003095. https:\/\/doi.org\/10.1371\/journal.pmed.1003095","journal-title":"PLoS Med"},{"issue":"22","key":"5262_CR13","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","volume":"40","author":"S Kojima","year":"2019","unstructured":"Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Mori H, Sugawara M, Ohya Y, Kimura K, Saito Y, Ogawa H (2019) Febuxostat for cerebral and cardiorenovascular events prevention study. Eur Heart J 40(22):1778\u20131786. https:\/\/doi.org\/10.1093\/eurheartj\/ehz119","journal-title":"Eur Heart J"},{"issue":"10","key":"5262_CR14","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N et al (2015) 2015 gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 74(10):1789\u20131798. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208237","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5262_CR15","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, MacDonald PA et al (2009) Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 36(6):1273\u20131282. https:\/\/doi.org\/10.3899\/jrheum.080814","journal-title":"J Rheumatol"},{"issue":"13","key":"5262_CR16","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.2165\/00003495-200868130-00007","volume":"68","author":"NL Edwards","year":"2008","unstructured":"Edwards NL (2008) Febuxostat : a viewpoint by N. Lawrence Edwards. Drugs 68(13):1875\u20131876. https:\/\/doi.org\/10.2165\/00003495-200868130-00007","journal-title":"Drugs"},{"key":"5262_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2318-12-11","volume":"12","author":"RL Jackson","year":"2012","unstructured":"Jackson RL, Hunt B, MacDonald PA (2012) The efficacy and safety of febuxostat for urate lowering in gout patients \u226565 years of age. BMC Geriatr 12:11. https:\/\/doi.org\/10.1186\/1471-2318-12-11","journal-title":"BMC Geriatr"},{"issue":"6","key":"5262_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/1756-185X.12266","volume":"17","author":"X Huang","year":"2014","unstructured":"Huang X, Du H, Gu J et al (2014) An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Int J Rheum Dis 17(6):679\u2013686. https:\/\/doi.org\/10.1111\/1756-185X.12266","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"5262_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.20452\/pamw.4001","volume":"127","author":"G Nuki","year":"2017","unstructured":"Nuki G, Doherty M, Richette P (2017) Current management of gout: practical messages from 2016 EULAR guidelines. Pol Arch Intern Med 127(4):267\u2013277. https:\/\/doi.org\/10.20452\/pamw.4001","journal-title":"Pol Arch Intern Med"},{"issue":"2","key":"5262_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/1759720X16682010","volume":"9","author":"A Waller","year":"2017","unstructured":"Waller A, Jordan KM (2017) Use of febuxostat in the management of gout in the United Kingdom. Ther Adv Musculoskelet Dis 9(2):55\u201364. https:\/\/doi.org\/10.1177\/1759720X16682010","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"11","key":"5262_CR21","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59(11):1540\u20131548. https:\/\/doi.org\/10.1002\/art.24209","journal-title":"Arthritis Rheum"},{"issue":"5","key":"5262_CR22","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1248\/bpb.b16-00972","volume":"40","author":"H Koide","year":"2017","unstructured":"Koide H, Hira D, Tsujimoto M, Katsube Y, Minegaki T, Uzu T, Ikeda Y, Morita SY, Nishiguchi K, Terada T (2017) Previous dosage of allopurinol is a strong determinant of febuxostat efficacy. Biol Pharm Bull 40(5):681\u2013686. https:\/\/doi.org\/10.1248\/bpb.b16-00972","journal-title":"Biol Pharm Bull"},{"key":"5262_CR23","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1007\/s10067-019-04737-5","volume":"38","author":"Z Mu","year":"2019","unstructured":"Mu Z, Wang W, Wang J, Lv W, Chen Y, Wang F, Yu X, Wang Y, Cheng B, Wang Z (2019) Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial. Clin Rheumatol 38:3511\u20133519. https:\/\/doi.org\/10.1007\/s10067-019-04737-5","journal-title":"Clin Rheumatol"},{"issue":"9","key":"5262_CR24","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2169\/internalmedicine.1899-18","volume":"58","author":"A Katayama","year":"2019","unstructured":"Katayama A, Yokokawa H, Fukuda H, Ono Y, Isonuma H, Hisaoka T, Naito T (2019) Achievement of target serum uric acid levels and factors associated with therapeutic failure among Japanese men treated for hyperuricemia\/gout. Intern Med 58(9):1225\u20131231. https:\/\/doi.org\/10.2169\/internalmedicine.1899-18","journal-title":"Intern Med"},{"issue":"2","key":"5262_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3810\/pgm.2014.03.2741","volume":"126","author":"H Hatoum","year":"2014","unstructured":"Hatoum H, Khanna D, Lin SJ et al (2014) Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. Postgrad Med 126(2):65\u201375. https:\/\/doi.org\/10.3810\/pgm.2014.03.2741","journal-title":"Postgrad Med"},{"key":"5262_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2147\/CEOR.S139939","volume":"9","author":"R Sheer","year":"2017","unstructured":"Sheer R, Null KD, Szymanski KA, Sudharshan L, Banovic J, Pasquale M (2017) Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat. Clinicoecon Outcomes Res 9:629\u2013639. https:\/\/doi.org\/10.2147\/CEOR.S139939","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"5262_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jjcc.2016.02.015","volume":"69","author":"S Kojima","year":"2017","unstructured":"Kojima S, Matsui K, Ogawa H, Jinnouchi H, Hiramitsu S, Hayashi T, Yokota N, Kawai N, Tokutake E, Uchiyama K, Sugawara M, Kakuda H, Wakasa Y, Mori H, Hisatome I, Waki M, Ohya Y, Kimura K, Saito Y, Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators (2017) Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. J Cardiol 69(1):169\u2013175. https:\/\/doi.org\/10.1016\/j.jjcc.2016.02.015","journal-title":"J Cardiol"},{"issue":"8","key":"5262_CR28","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/art.39654","volume":"68","author":"KG Saag","year":"2016","unstructured":"Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L (2016) Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment. Arthritis Rheumatol 68(8):2035\u20132043. https:\/\/doi.org\/10.1002\/art.39654","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"5262_CR29","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","volume":"66","author":"D Sircar","year":"2015","unstructured":"Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, Pandey R (2015) Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, Placebo-Controlled Trial. Am J Kidney Dis 66(6):945\u2013950. https:\/\/doi.org\/10.1053\/j.ajkd.2015.05.017","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"5262_CR30","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/hdi.12313","volume":"19","author":"Y Tsuruta","year":"2015","unstructured":"Tsuruta Y, Kikuchi K, Tsuruta Y, Sasaki Y, Moriyama T, Itabashi M, Takei T, Uchida K, Akiba T, Tsuchiya K, Nitta K (2015) Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: a randomized controlled study. Hemodial Int 19(4):514\u2013520. https:\/\/doi.org\/10.1111\/hdi.12313","journal-title":"Hemodial Int"},{"key":"5262_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40780-015-0028-1","volume":"1","author":"S Mitsuboshi","year":"2015","unstructured":"Mitsuboshi S, Yamada H, Nagai K, Okajima H (2015) Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients. J Pharm Health Care Sci 1:28. https:\/\/doi.org\/10.1186\/s40780-015-0028-1","journal-title":"J Pharm Health Care Sci"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05262-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05262-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05262-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T19:55:27Z","timestamp":1624996527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05262-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["5262"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05262-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"assertion":[{"value":"16 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Disclosures None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}